Tango Therapeutics, Inc.
TNGX
$10.08
-$0.34-3.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 66.50M | 24.30M | 40.99M | 42.07M | 43.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.50M | 24.30M | 40.99M | 42.07M | 43.38M |
| Cost of Revenue | 134.00M | 136.45M | 142.30M | 143.92M | 141.32M |
| Gross Profit | -67.50M | -112.15M | -101.31M | -101.85M | -97.94M |
| SG&A Expenses | 42.84M | 45.13M | 44.57M | 43.75M | 41.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 176.84M | 181.58M | 186.86M | 187.67M | 183.08M |
| Operating Income | -110.34M | -157.29M | -145.87M | -145.60M | -139.70M |
| Income Before Tax | -100.41M | -145.39M | -132.06M | -130.09M | -123.19M |
| Income Tax Expenses | 108.00K | 172.00K | 202.00K | 208.00K | 206.00K |
| Earnings from Continuing Operations | -100.52 | -145.57 | -132.26 | -130.30 | -123.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.52M | -145.57M | -132.26M | -130.30M | -123.40M |
| EBIT | -110.34M | -157.29M | -145.87M | -145.60M | -139.70M |
| EBITDA | -107.91M | -154.80M | -143.37M | -143.10M | -137.20M |
| EPS Basic | -0.92 | -1.33 | -1.21 | -1.20 | -1.17 |
| Normalized Basic EPS | -0.55 | -0.81 | -0.74 | -0.74 | -0.73 |
| EPS Diluted | -0.93 | -1.33 | -1.21 | -1.20 | -1.17 |
| Normalized Diluted EPS | -0.56 | -0.81 | -0.74 | -0.74 | -0.73 |
| Average Basic Shares Outstanding | 440.49M | 438.03M | 435.81M | 433.68M | 422.22M |
| Average Diluted Shares Outstanding | 447.31M | 438.03M | 435.81M | 433.68M | 422.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |